Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.

NDA204114: MEKINIST

  • FDA application ID: NDA204114
  • Type: Approval
  • Active ingredients: TRAMETINIB DIMETHYL SULFOXIDE

Conditions

Interventions

Lay summary

This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Documents

 

Publications

We have no "publications" for this trial. Help us by contributing data.

Registries